Condition: Bladder Cancer · Sponsor: University College, London
DURANCE is a two part, phase Ib/II, multi-centre study to assess the safety and activity of S-488210/S-488211 in combination with durvalumab, in patients with non-muscle invasive bladder cancer (NMIBC).
This description comes directly from the study's public registry record.
Madison Williams · 02076799514 · ctc.durance@ucl.ac.uk
Rubina Begum · 02076799514 · rubina.begum@ucl.ac.uk
Always discuss trial participation with your own doctor first.
| Cambridge University NHS FT | Cambridge, United Kingdom | Recruiting |
| Guy's and St Thomas' NHS Foundation Trust | London, United Kingdom | Recruiting |
| Royal Free London NHS FT | London, United Kingdom | Recruiting |
| The Royal Marsden NHS Foundation Trust | London, United Kingdom | Recruiting |
| University College London Hospital NHS Foundation Trust | London, United Kingdom | Recruiting |
| The Christie NHS Foundation Trust | Manchester, United Kingdom | Recruiting |
| University Hospital Southampton NHS Foundation Trust | Southampton, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04106115